2019 Q4 Form 10-K Financial Statement
#000155837021002222 Filed on March 02, 2021
Income Statement
Concept | 2019 Q4 | 2018 | 2017 Q4 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $3.870M | $11.41M | $2.820M |
YoY Change | 32.53% | 16.07% | 22.61% |
% of Gross Profit | |||
Research & Development | $11.47M | $40.09M | $6.720M |
YoY Change | -4.73% | 66.36% | 10.89% |
% of Gross Profit | |||
Depreciation & Amortization | $70.00K | $275.1K | $70.00K |
YoY Change | 0.0% | 5.82% | 40.0% |
% of Gross Profit | |||
Operating Expenses | $15.34M | $51.50M | $9.540M |
YoY Change | 2.54% | 51.8% | 14.11% |
Operating Profit | -$51.50M | ||
YoY Change | |||
Interest Expense | $610.0K | $3.231M | $280.0K |
YoY Change | -41.9% | 397.11% | 833.33% |
% of Operating Profit | |||
Other Income/Expense, Net | |||
YoY Change | |||
Pretax Income | -$14.73M | -$48.27M | -$9.260M |
YoY Change | 5.9% | 45.04% | 11.16% |
Income Tax | $0.00 | $0.00 | |
% Of Pretax Income | |||
Net Earnings | -$14.73M | -$48.27M | -$9.260M |
YoY Change | 5.9% | 45.05% | 11.16% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$339.6K | -$1.176M | -$271.2K |
COMMON SHARES | |||
Basic Shares Outstanding | |||
Diluted Shares Outstanding |
Balance Sheet
Concept | 2019 Q4 | 2018 | 2017 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $158.2M | $209.9M | $123.9M |
YoY Change | -24.63% | 69.41% | 208.98% |
Cash & Equivalents | $158.2M | $209.9M | $123.9M |
Short-Term Investments | $0.00 | ||
Other Short-Term Assets | $4.100M | $1.900M | $3.200M |
YoY Change | 115.79% | -40.63% | 1500.0% |
Inventory | |||
Prepaid Expenses | $3.839M | ||
Receivables | |||
Other Receivables | $186.0K | ||
Total Short-Term Assets | $162.5M | $212.3M | $127.2M |
YoY Change | -23.44% | 66.9% | 214.07% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $822.9K | $1.000M | $1.100M |
YoY Change | -17.71% | -9.09% | 0.0% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $1.600M | $1.600M | $300.0K |
YoY Change | 0.0% | 433.33% | -62.5% |
Total Long-Term Assets | $5.442M | $2.500M | $1.400M |
YoY Change | 117.68% | 78.57% | -26.32% |
TOTAL ASSETS | |||
Total Short-Term Assets | $162.5M | $212.3M | $127.2M |
Total Long-Term Assets | $5.442M | $2.500M | $1.400M |
Total Assets | $168.0M | $214.8M | $128.6M |
YoY Change | -21.8% | 67.03% | 203.3% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.436M | $2.700M | $2.600M |
YoY Change | -46.83% | 3.85% | 62.5% |
Accrued Expenses | $8.711M | $6.000M | $5.400M |
YoY Change | 45.18% | 11.11% | 14.89% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $10.95M | $8.800M | $8.200M |
YoY Change | 24.44% | 7.32% | 30.16% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $2.800M | $600.0K | $700.0K |
YoY Change | 366.67% | -14.29% | -12.5% |
Total Long-Term Liabilities | $2.800M | $600.0K | $700.0K |
YoY Change | 366.67% | -14.29% | -12.5% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $10.95M | $8.800M | $8.200M |
Total Long-Term Liabilities | $2.800M | $600.0K | $700.0K |
Total Liabilities | $13.77M | $9.400M | $8.900M |
YoY Change | 46.48% | 5.62% | 25.35% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$258.4M | ||
YoY Change | |||
Common Stock | $43.47K | ||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $154.2M | $205.5M | $119.7M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $168.0M | $214.8M | $128.6M |
YoY Change | -21.8% | 67.03% | 203.3% |
Cashflow Statement
Concept | 2019 Q4 | 2018 | 2017 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$14.73M | -$48.27M | -$9.260M |
YoY Change | 5.9% | 45.05% | 11.16% |
Depreciation, Depletion And Amortization | $70.00K | $275.1K | $70.00K |
YoY Change | 0.0% | 5.82% | 40.0% |
Cash From Operating Activities | -$12.79M | -$43.33M | -$8.370M |
YoY Change | 28.16% | 45.55% | 40.67% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$10.00K | $125.6K | -$30.00K |
YoY Change | -83.33% | -143.32% | -93.02% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | |||
YoY Change | |||
Cash From Investing Activities | -$10.00K | -$125.6K | -$30.00K |
YoY Change | -83.33% | -56.68% | -93.02% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $128.4M | ||
YoY Change | 12.7% | ||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 120.0K | 129.4M | 19.46M |
YoY Change | -7.69% | 13.6% | 1592.17% |
NET CHANGE | |||
Cash From Operating Activities | -12.79M | -43.33M | -8.370M |
Cash From Investing Activities | -10.00K | -125.6K | -30.00K |
Cash From Financing Activities | 120.0K | 129.4M | 19.46M |
Net Change In Cash | -12.68M | 85.99M | 11.06M |
YoY Change | 27.95% | 2.51% | -311.47% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$12.79M | -$43.33M | -$8.370M |
Capital Expenditures | -$10.00K | $125.6K | -$30.00K |
Free Cash Flow | -$12.78M | -$43.46M | -$8.340M |
YoY Change | 28.83% | 47.41% | 51.09% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2020 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
||
CY2019Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
||
CY2020 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2020 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001253689 | |
CY2020 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2020 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | |
CY2020 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2020 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2020 | us-gaap |
Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
|
true | |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
49017622 | |
CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
43466933 | |
CY2020Q4 | us-gaap |
Lease Practical Expedient Lessor Single Lease Component
LeasePracticalExpedientLessorSingleLeaseComponent
|
true | |
CY2020 | us-gaap |
Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
|
true | |
CY2020 | dei |
Document Type
DocumentType
|
10-K | |
CY2020 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-12-31 | |
CY2020 | dei |
Entity File Number
EntityFileNumber
|
001-36177 | |
CY2020 | dei |
Entity Registrant Name
EntityRegistrantName
|
GlycoMimetics, Inc. | |
CY2020 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2020 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
06-1686563 | |
CY2020 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
9708 Medical Center Drive | |
CY2020 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Rockville | |
CY2020 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MD | |
CY2020 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
20850 | |
CY2020 | dei |
City Area Code
CityAreaCode
|
240 | |
CY2020 | dei |
Local Phone Number
LocalPhoneNumber
|
243-1201 | |
CY2020 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.001 par value | |
CY2020 | dei |
Trading Symbol
TradingSymbol
|
GLYC | |
CY2020 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2020 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2020 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2020 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2020 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2020 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2020 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2020 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2020 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2020 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
false | |
CY2020Q2 | dei |
Entity Public Float
EntityPublicFloat
|
137800000 | |
CY2021Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
51493571 | |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
137035017 | |
CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
158201441 | |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1238328 | |
CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4326322 | |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
138273345 | |
CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
162527763 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
620673 | |
CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
822920 | |
CY2020Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
1560607 | |
CY2019Q4 | us-gaap |
Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
|
1560607 | |
CY2020Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
52320 | |
CY2019Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
52320 | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
2325224 | |
CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3006069 | |
CY2020Q4 | us-gaap |
Assets
Assets
|
142832169 | |
CY2019Q4 | us-gaap |
Assets
Assets
|
167969679 | |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2089939 | |
CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1435660 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9439881 | |
CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8710790 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
898549 | |
CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
804126 | |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12428369 | |
CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10950576 | |
CY2020Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
|
264329 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1920015 | |
CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
2818516 | |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
14612713 | |
CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
13769092 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
49017622 | |
CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
43466933 | |
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
49018 | |
CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
43465 | |
CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
437639991 | |
CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
412599772 | |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-309469553 | |
CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-258442650 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
128219456 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
154200587 | |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
142832169 | |
CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
167969679 | |
CY2020 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
10162935 | |
CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44929198 | |
CY2019 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
47029264 | |
CY2018 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
40091773 | |
CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
16743127 | |
CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
14360038 | |
CY2018 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11413050 | |
CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
61672325 | |
CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
61389302 | |
CY2018 | us-gaap |
Operating Expenses
OperatingExpenses
|
51504823 | |
CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-51509390 | |
CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-61389302 | |
CY2018 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-51504823 | |
CY2020 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
482487 | |
CY2019 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
3497391 | |
CY2018 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
3231190 | |
CY2020 | glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-51026903 | |
CY2019 | glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-57891911 | |
CY2018 | glyc |
Net Income Loss And Comprehensive Income Net Of Tax
NetIncomeLossAndComprehensiveIncomeNetOfTax
|
-48273633 | |
CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.12 | |
CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.34 | |
CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.18 | |
CY2020 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
45721139 | |
CY2019 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
43254782 | |
CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
41044621 | |
CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
119701425 | |
CY2018 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
128425080 | |
CY2020 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
319297 | |
CY2018 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
128425080 | |
CY2018 | glyc |
Stock Issued During Period Value Stock Options And Warrants And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndWarrantsAndRestrictedStockUnitsVesting
|
1024525 | |
CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
4587098 | |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-48273633 | |
CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
205464495 | |
CY2019 | glyc |
Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
|
412913 | |
CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6215090 | |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-57891911 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
154200587 | |
CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
17824717 | |
CY2020 | glyc |
Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
|
319297 | |
CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
6901758 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-51026903 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
128219456 | |
CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-51026903 | |
CY2019 | us-gaap |
Profit Loss
ProfitLoss
|
-57891911 | |
CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-48273633 | |
CY2020 | us-gaap |
Depreciation
Depreciation
|
270754 | |
CY2019 | us-gaap |
Depreciation
Depreciation
|
279234 | |
CY2018 | us-gaap |
Depreciation
Depreciation
|
275123 | |
CY2018 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-168 | |
CY2020 | glyc |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
680845 | |
CY2019 | glyc |
Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
|
620068 | |
CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6901758 | |
CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6215090 | |
CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4587098 | |
CY2020 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-3087994 | |
CY2019 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2059260 | |
CY2018 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-943360 | |
CY2018 | glyc |
Increase Decrease In Prepaid Research And Development Expenses
IncreaseDecreaseInPrepaidResearchAndDevelopmentExpenses
|
1356243 | |
CY2020 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
654279 | |
CY2019 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1227919 | |
CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
16488 | |
CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
729091 | |
CY2019 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
2709986 | |
CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
551146 | |
CY2020 | glyc |
Increase Decrease In Noncurrent Accrued Liabilities
IncreaseDecreaseInNoncurrentAccruedLiabilities
|
264329 | |
CY2018 | glyc |
Increase Decrease Deferred Rent Credit
IncreaseDecreaseDeferredRentCredit
|
-74637 | |
CY2020 | glyc |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-804078 | |
CY2019 | glyc |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-629427 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-39241931 | |
CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-51984139 | |
CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-43331130 | |
CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
68507 | |
CY2019 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
144928 | |
CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
125618 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-68507 | |
CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-144928 | |
CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-125618 | |
CY2020 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
17824717 | |
CY2019 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
412913 | |
CY2018 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
1024525 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
18144014 | |
CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
412913 | |
CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
129449605 | |
CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-21166424 | |
CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-51716154 | |
CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
85992857 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
158201441 | |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
209917595 | |
CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
123924738 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
137035017 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
158201441 | |
CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
209917595 | |
CY2020 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">1. Description of the Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The company is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the Company is developing a pipeline of proprietary glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The Company’s executive personnel have devoted substantially all of their time to date to the planning and organization of the Company, the process of hiring scientists, initiating research and development programs and securing adequate capital for anticipated growth and operations. The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company has incurred significant losses in the development of its drug candidates. The Company has not generated revenues from product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had an accumulated deficit of $309.5 million at December 31, 2020 and expects to continue incurring losses for the foreseeable future.</p> | |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-309500000 | |
CY2020 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> | |
CY2020 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents consist of investment in money market funds with major financial institutions in the United States. These deposits and funds may be redeemed upon demand and, therefore, bear minimal risk. The Company does not anticipate any losses on such balances.</p> | |
CY2019 | glyc |
Number Of Long Lived Assets Determined To Be Impaired
NumberOfLongLivedAssetsDeterminedToBeImpaired
|
0 | |
CY2020 | glyc |
Number Of Long Lived Assets Determined To Be Impaired
NumberOfLongLivedAssetsDeterminedToBeImpaired
|
0 | |
CY2019Q4 | us-gaap |
Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
|
0 | |
CY2020Q4 | us-gaap |
Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
|
0 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-51026903 | |
CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-57891911 | |
CY2018 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-48273633 | |
CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.12 | |
CY2019 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.34 | |
CY2018 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.18 | |
CY2020 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
45721139 | |
CY2019 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
43254782 | |
CY2018 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
41044621 | |
CY2019Q4 | glyc |
Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
|
1308102 | |
CY2020Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
965504 | |
CY2019Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
3838835 | |
CY2020Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
270675 | |
CY2019Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
301534 | |
CY2020Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
2149 | |
CY2019Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
185953 | |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1238328 | |
CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4326322 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2752972 | |
CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2684465 | |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2132299 | |
CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1861545 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
620673 | |
CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
822920 | |
CY2020 | us-gaap |
Depreciation
Depreciation
|
270754 | |
CY2019 | us-gaap |
Depreciation
Depreciation
|
279234 | |
CY2018 | us-gaap |
Depreciation
Depreciation
|
275123 | |
CY2020Q4 | glyc |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5114420 | |
CY2019Q4 | glyc |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5149697 | |
CY2020Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
3341184 | |
CY2019Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
2677288 | |
CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
194760 | |
CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
320935 | |
CY2020Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
569048 | |
CY2019Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
351966 | |
CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
220469 | |
CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
210904 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
9439881 | |
CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8710790 | |
CY2020 | glyc |
Debt Instrument Interest Incremental Borrowing Rate Percentage
DebtInstrumentInterestIncrementalBorrowingRatePercentage
|
0.08 | |
CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y9M18D | |
CY2020 | glyc |
Lessee Operating Lease Number Of New Leases
LesseeOperatingLeaseNumberOfNewLeases
|
0 | |
CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
927957 | |
CY2019 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
927957 | |
CY2020 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
593973 | |
CY2019 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
465028 | |
CY2020 | us-gaap |
Lease Cost
LeaseCost
|
1521930 | |
CY2019 | us-gaap |
Lease Cost
LeaseCost
|
1392985 | |
CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1051190 | |
CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
941089 | |
CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4587098 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
63830866 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1077420 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1104356 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
940890 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
0 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
3122666 | |
CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
304102 | |
CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
2818564 | |
CY2018Q4 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
553868 | |
CY2018Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.33 | |
CY2018 | glyc |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
546709 | |
CY2018 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
2336 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.17 | |
CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
7.17 | |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.90 | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | |
CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | |
CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8440 | |
CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7115 | |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7375 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0141 | |
CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0254 | |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0255 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6901758 | |
CY2019 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
6215090 | |
CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
-0.001 | |
CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
53391629 | |
CY2020Q4 | glyc |
Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
|
1114309 | |
CY2020Q4 | glyc |
Deferred Tax Assets Patent Amortization
DeferredTaxAssetsPatentAmortization
|
88949 | |
CY2019Q4 | glyc |
Deferred Tax Assets Patent Amortization
DeferredTaxAssetsPatentAmortization
|
104419 | |
CY2020Q4 | glyc |
Deferred Tax Assets Research And Orphan Drug Credits
DeferredTaxAssetsResearchAndOrphanDrugCredits
|
42008797 | |
CY2019Q4 | glyc |
Deferred Tax Assets Research And Orphan Drug Credits
DeferredTaxAssetsResearchAndOrphanDrugCredits
|
35211702 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
|
6778569 | |
CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
|
4935232 | |
CY2020Q4 | glyc |
Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
|
775598 | |
CY2019Q4 | glyc |
Deferred Tax Assets Tax Deferred Expense Operating Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseOperatingLeaseLiabilities
|
996861 | |
CY2020Q4 | glyc |
Deferred Tax Assets Accrued Bonus
DeferredTaxAssetsAccruedBonus
|
919410 | |
CY2019Q4 | glyc |
Deferred Tax Assets Accrued Bonus
DeferredTaxAssetsAccruedBonus
|
736723 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
283751 | |
CY2019Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
136641 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
115800249 | |
CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
96821309 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
115016323 | |
CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
95850031 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
783926 | |
CY2019Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
971278 | |
CY2020Q4 | glyc |
Deferred Tax Liabilities Tax Deferred Expense Operating Lease Liabilities Right Of Use Assets
DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets
|
639843 | |
CY2019Q4 | glyc |
Deferred Tax Liabilities Tax Deferred Expense Operating Lease Liabilities Right Of Use Assets
DeferredTaxLiabilitiesTaxDeferredExpenseOperatingLeaseLiabilitiesRightOfUseAssets
|
827195 | |
CY2020Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
144083 | |
CY2019Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
144083 | |
CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
783926 | |
CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
971278 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.057 | |
CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.057 | |
CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.057 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.007 | |
CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.008 | |
CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.008 | |
CY2020 | glyc |
Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent
EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
|
0.098 | |
CY2019 | glyc |
Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent
EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
|
0.088 | |
CY2018 | glyc |
Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent
EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
|
0.104 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
0.004 | |
CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
|
0.006 | |
CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.001 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.376 | |
CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.362 | |
CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.384 | |
CY2019 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.50 | |
CY2020 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.50 | |
CY2018 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.50 | |
CY2020 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
252000 | |
CY2019 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
219000 | |
CY2018 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
94000 | |
CY2020 | us-gaap |
Loss Contingency Disclosures
LossContingencyDisclosures
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">12. Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27pt;margin:0pt 0pt 6pt 0pt;">In March 2020, the World Health Organization declared the novel coronavirus disease 2019, or COVID-19, outbreak a pandemic. In order to mitigate the spread of COVID-19, governments have imposed unprecedented restrictions on business operations, travel and gatherings, resulting in a global economic downturn and other adverse economic and societal impacts. The COVID-19 pandemic has also overwhelmed or otherwise led to changes in the operations of many healthcare facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The impact of the COVID-19 pandemic on the Company’s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of “lockdown,” “social distancing” and “shelter in place” directives by state and federal governments in the United States as well as governments in other regions of the world in response to the COVID-19 pandemic, including in locations in which its Phase 3 clinical trial of uproleselan is being conducted, resulted in slowed clinical site initiation, patient recruitment and enrollment rates early in the pandemic. Enrollment rates have returned to forecasted levels since the lockdowns. However, the COVID-19 infection rates continue to fluctuate which could negatively affect enrollment going forward. The Company is unable to determine the extent of the impact of the pandemic on its operations and financial condition going forward. These developments are highly uncertain and unpredictable, and may materially adversely affect the Company’s financial position and results of operations. The Company continues to closely monitor the COVID-19 situation and any potential impact to its planned activities.</p> |